33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma
    Meeting Abstract

    Chapman, P. B.; Hauschild, A.; Robert, C.; Larkin, J. M. G.; Haanen, J. B. A. G.; Ribas, A.; Hogg, D.; O'Day, S.; Ascierto, P. A.; Testori, A.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    Meeting Abstract

    Aghajanian, C.; Finkler, N. J.; Rutherford, T.; Smith, D. A.; Yi, J.; Parmar, H.; Nycum, L. R.; Sovak, M. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Randomized double-blind placebo-controlled international trial of abago-vomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abago-vomab (MIMOSA) trial
    Meeting Abstract

    Pfisterer, J.; Berek, J. S.; Casado, A.; Cwiertka, K.; Pinter, T.; Pluzanska, A.; Pujade-Lauraine, E.; Scambia, G.; Vermorken, J. B.; Simonelli, C.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel
    Meeting Abstract

    Scher, H. I.; Heller, G.; Molina, A.; Kheoh, T. S.; Attard, G.; Moreira, J.; Sandhu, S. K.; Parker, C.; Logothetis, C.; McCormack, R. T.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Development and validation of a prediction tool for hand-foot skin reaction (HFSR) in patients receiving sorafenib
    Meeting Abstract

    Yu, J.; Dranitsaris, G.; Vincent, M. D.; Huang, L.; Fang, F.; Lacouture, M. E.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Can we really treat patients older than age 70 with a chemotherapy doublet for non-small cell lung cancer (NSCLC)?
    Meeting Abstract

    Zauderer, M. G.; Sima, C. S.; Korc-Grodzicki, B.; Kris, M. G.; Krug, L. M.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Metrics for measuring tumor burden: A comparison of unidimensional and volumetric measurements
    Meeting Abstract

    Zhao, B.; Ghiorghiu, D. C.; Lefkowitz, R. A.; Marley, S. E.; Tan, Y.; Scott, M. L.; Mann, H.; Schwartz, L. H.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Kris, M. G.; Johnson, B. E.; Kwiatkowski, D. J.; Iafrate, A. J.; Wistuba, I. I.; Aronson, S. L.; Engelman, J. A.; Shyr, Y.; Khuri, F. R.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Clinical features of germ cell tumors (GCT) in men age 50 or older: Successful outcome and tolerability to chemotherapy for advanced disease
    Meeting Abstract

    Voss, M. H.; Jacobsen, E. P.; Patil, S.; Turkula, S.; Jia, X.; Sheinfeld, J.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.; Feldman, D. R.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Tumor microenvironment derived biomarkers for the early detection of pancreatic cancer (PDAC)
    Meeting Abstract

    Wehr, A. Y.; Blair, I. A.; Yu, K. H.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save